A combined oncogenic pathway signature of braf, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction

Medicine and Dentistry

• Patient 83%
• Neoplasm 50%
• Colorectal Cancer 50%
• Cetuximab 50%
• Gene 50%
• Epidermal Growth Factor Receptor 33%
• Metastatic Colorectal Cancer 33%
• Therapeutic Procedure 33%
• Gene Expression 16%
• Signal Transduction 16%
• Microarray 16%
• Development 16%
• Cancer Classification 16%
• Inpatient 16%
• Mitogen-Activated Protein Kinase 16%

Biochemistry, Genetics and Molecular Biology

• KRAS 100%
• Mutation 83%
• Nested Gene 50%
• Cetuximab 50%
• Epidermal Growth Factor Receptor 33%
• Gene Expression 16%
• Signal Transduction 16%
• Development 16%
• Cancer Classification 16%
• Sample 16%
• MAPK/ERK Pathway 16%
• Microarray 16%